• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Weintraub Bennett

    10/17/25 7:10:41 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APUS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Weintraub Bennett

    (Last) (First) (Middle)
    C/O APIMEDS PHARMACEUTICALS US, INC.
    100 MATAWAN ROAD, SUITE 325

    (Street)
    MATAWAN NJ 07747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Apimeds Pharmaceuticals US, Inc. [ APUS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $1.92 10/15/2025 A 3,000 (1) 10/15/2035 Common Stock, par value $0.01 per share 3,000 $0 3,000 D
    Explanation of Responses:
    1. The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.
    Remarks:
    Exhibit List: Ex. 24.1 - Power of Attorney
    /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 10/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APUS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CMO Kim Christopher bought $50,359 worth of shares (27,500 units at $1.83) (SEC Form 4)

    4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

    5/15/25 6:48:30 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Koo Jakap bought $56,715 worth of shares (28,500 units at $1.99), increasing direct ownership by 5% to 643,885 units (SEC Form 4)

    4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

    5/14/25 5:58:18 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Inscobee Inc. bought $2,000,000 worth of shares (500,000 units at $4.00) and converted options into 297,133 shares, increasing direct ownership by 37% to 2,028,657 units (SEC Form 4)

    4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

    5/14/25 5:52:52 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Large owner Inscobee Inc.

    4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

    11/21/25 9:26:11 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Weintraub Bennett

    4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

    11/13/25 6:43:03 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Yoon Hankil

    4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

    11/13/25 6:39:55 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    E.F. Hutton Advises on Strategic Merger Between Apimeds and MindWave, Aligning Biotech Growth with AI-Enabled Financial Innovation

    NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds Pharmaceuticals US Inc. (NYSE:APUS) and Mindwave Innovations Inc. The merger brings together a biotech development platform with an AI-powered digital treasury infrastructure supported by a $100 million PIPE commitment, for which E.F. Hutton acted as Placement Agent. E.F. Hutton's involvement underscores its commitment to advancing the combined company's strategic growth across late-stage biotech development and institutional Digital Asset Treasury Solutions. E.F. Hutton worked closely with both companies to shape the transaction fram

    12/17/25 8:00:00 AM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy

    Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment reinforces the Company's financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones. The financing also facilitates the integration of MindWave Innovations Inc., aligning corporate operations and financial management processes. As part of that integration, approximately 1,000 Bitcoin previously held by MindWave have been transferred into a segregated, risk-managed structure. This digital-asset position is governed under a defined inv

    12/10/25 9:58:00 AM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE

    Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven Bitcoin treasury, digital asset yield generation, and $NILA-powered ecosystem. The combined company integrates high-growth biotechnology and institutional digital-treasury capabilities, with the merger supported by a simultaneous PIPE of up to $100 million to advance Apimeds' clinical programs and expand MindWave's digital asset infrastructure. (NYSE:APUS) Apimeds Pharmaceuticals US, Inc. ("Apimeds"), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that i

    12/1/25 9:25:00 AM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APUS
    SEC Filings

    View All

    SEC Form PREM14C filed by Apimeds Pharmaceuticals US Inc.

    PREM14C - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

    1/16/26 4:35:58 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Leadership Update

    8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

    1/2/26 4:30:52 PM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Leadership Update

    8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

    12/10/25 9:20:06 AM ET
    $APUS
    Biotechnology: Pharmaceutical Preparations
    Health Care